Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos to Acquire Inpharmatica for as Much as $25.4M

NEW YORK (GenomeWeb News) — Galapagos today said it plans to acquire Inpharmatica, a UK-based drug discovery database company in a stock deal that potentially worth €19.1 million ($25.4 million).
Galapagos said it estimates that Inpharmatica’s ongoing business is worth €6.5 million, the company has €6 million for the cash, and has a potential to earn around €6.6 million in milestones.
Inpharmatica will become part of Galapagos’ drug-discovery branch, BioFocus DPI, and will contribute its Admensa chemical compound screening and Chematica chemoinformatics services to expand client services.
Galapagos CEO Onno van de Stolpe said the deal “will position our company further for additional turn-key deals ranging from target discovery all the way to clinical proof of concept.”
Galapagos also said it expects to lay-off some of Inpharmatica’s management, sales, and administrative staff.
Under the terms of the agreement, Galapagos will issue as many as 2.2 million of its shares at €8.82 apiece — or around €19.1 million — which was the trading price over the 30 days before Dec. 5. Galapagos said it will issue these shares “assuming that all three components” — milestones, cash on hand, and Inpharmatica’s worth as an ongoing business — “are fully delivered.”
To facilitate the deal, Galapagos said it will apply for a listing for the new Galapagos shares on Euronext Brussels and Euronext Amsterdam.

Filed under

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.